Skip to Content

FLT3 Inhibitor Gilteritinib Shows Potential in Post-Transplant Maintenance for AML

The phase 3 randomized MORPHO trial, presented as an LBA at EHA23, did not meet its primary endpoint. However, the results are still indeed promising as they provide valuable guidance for identifying patients who would benefit from the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. In this MEDtalk, Professor Mark J. Levis from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, explains the implications of the findings for clinical practice and identifies the patient groups that should be considered for this treatment.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top